According to preliminary data from a multi-institution phase III trial led by researchers at MD Anderson Cancer Center, intensity modulated proton therapy achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy as part of chemoradiation treatment for patients with oropharyngeal cancer.
Neal J. Meropol was named principal investigator of the American Society of Clinical Oncology’s Targeted Agent and Profiling Utilization Registry study.
